Correlation Between Estimated Glomerular Filtration Rate(eGFR) and Vascular Inflammation Measured by Positron Emission Tomography (PET) With 18F-fluoro-deoxyglucose (FDG)
NCT ID: NCT02394743
Last Updated: 2016-09-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
360 participants
OBSERVATIONAL
2011-03-31
2016-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a promising tool for identifying and quantifying vascular inflammation within atherosclerotic plaques.Therefore, the purpose of the study is to demonstrate the correlation between eGFR and vascular inflammation detected by 18F FDG-PET.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Association Between Framingham Risk Score, hsCRP and Vascular Inflammation: Analysis With 18F-Fluorodeoxyglucose Positron Emission Tomography
NCT01139827
Multimodal Imaging Assessment of Chronic Kidney Disease Patients at Different Stages From a Cardio-Renal Interaction Perspective
NCT07107919
PET Image in PAH Patients
NCT05452889
PET and Recovery Following Revascularization (PARR 2)
NCT00385242
Renal Perfusion Assessment in the Endovascular Treatment of Renal Artery Stenosis
NCT05603221
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
eGFR > 90
group whose eGFR is more than 90
18FDG-PET
60 < eGFR <90
group whose eGFR is between 60 and 90
18FDG-PET
eGFR < 60
group whose eGFR is less than 60
18FDG-PET
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
18FDG-PET
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. \>=30 years of age;
3. no prior history of cardiovascular disease ; and
4. absence of acute or chronic inflammatory or autoimmune disease (based on documented medical history) or use of chronic anti-inflammatory therapy.
Exclusion Criteria
2. presence of chronic inflammatory disease
3. use of anti-inflammatory medications
4. presence of active malignant cancer (defined as any radiological or pathological evidence of malignant cancer disease or undergoing chemotherapy or radiation therapy within 1 year before initial PET/CT and throughout the inter-scan duration).
30 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Korea University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kyung Mook Choi
Medical professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Internal Medicine, Korea University College of Medicine
Seoul, VD, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PET_eGRF
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.